0001470831-25-000129.txt : 20250814 0001470831-25-000129.hdr.sgml : 20250814 20250814145707 ACCESSION NUMBER: 0001470831-25-000129 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250814 DATE AS OF CHANGE: 20250814 EFFECTIVENESS DATE: 20250814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KAZIA THERAPEUTICS LTD CENTRAL INDEX KEY: 0001075880 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-554781 FILM NUMBER: 251217807 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24, STREET 2: 300 BARANGAROO AVENUE CITY: SYDNEY NSW PROVINCE COUNTRY: C3 ZIP: 2000 BUSINESS PHONE: 01161298780088 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24, STREET 2: 300 BARANGAROO AVENUE CITY: SYDNEY NSW PROVINCE COUNTRY: C3 ZIP: 2000 FORMER COMPANY: FORMER CONFORMED NAME: NOVOGEN LTD DATE OF NAME CHANGE: 19981228 D 1 primary_doc.xml X0708 D LIVE 0001075880 KAZIA THERAPEUTICS LTD THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 AUSTRALIA 2000 01161298780088 AUSTRALIA NOVOGEN LTD Corporation true John Friend Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Bryce Carmine Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Steven Coffey Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Ebru Davidson Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Robert Apple Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Jeffrey Bonacorda Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Elissa Hansen Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Biotechnology Decline to Disclose 06b false 2025-08-04 false true true true false 0 2050013 2050013 0 Includes pre-funded warrants to purchase up to 204,547 ADSs, each representing 500 ordinary shares, and aggregate exercise price of ADSs underlying pre-funded warrants, each exercisable for one ADS at exercise price $0.0001 per ADS. false 4 0 0 0 false KAZIA THERAPEUTICS LTD /s/ John Friend John Friend Chief Executive Officer 2025-08-14